Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review
1 through 10 of 18

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

Study : Promising early results for people with DNA mismatch repair deficient rectal cancer

Most relevant for: People with rectal cancer with high mutational burden or mismatch repair problems including people with Lynch syndrome.

A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Human Research

Study : Prostate cancer screening may benefit people with Lynch syndrome

Most relevant for: People with Lynch syndrome

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Study : Resistant starch may help prevent some cancers in people with Lynch syndrome

Most relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome

This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Screening for pancreatic cancer detects early-stage disease and improves survival

Most relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.

A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer

Most relevant for: people with metastatic or recurrent cancer

In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Update : Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer

Most relevant for: People with recurrent or advanced endometrial cancer

The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome

Most relevant for: People with Lynch syndrome

Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer

Most relevant for: People with advanced colorectal cancer and a type of biomarker called MSI-High (MSI-H)

In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

Study : Inherited gene mutations found in pancreatic cancer families in Spain

Most relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers

This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Cancer risk associated with inherited mutations in Lynch syndrome genes

Most relevant for: People with Lynch syndrome mutations

Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)

Read More